Venue: New york city, New York
The aim of the conference is to review the current state and to pave the road to the new developments in the basic, translational and clinical research in cutaneous lymphomas and other lymphoproliferative disorders. The technological advances have enabled numerous recent discoveries in genomic and mutational landscapes in cutaneous lymphomas, which have significant implications for development of true personalized approaches to therapy. In this context, the congress will specifically focus on the basic, translational and clinical aspects of the exciting new developments, including biomarkers and molecular pathways analysis, targeted therapies, including novel antibodies specific for cell surface molecules that direct toxins, immune therapies, kinase inhibitors, and combination therapies among others.
More information on the conference website.